No. 24-456

Boehringer Ingelheim Pharmaceuticals, Inc., et al. v. Beth Bacher, Representative for Paul Bacher, Deceased, et al.

Lower Court: Second Circuit
Docketed: 2024-10-23
Status: Denied
Type: Paid
Tags: class-action-fairness-act federal-removal mass-action statutory-interpretation subject-matter-jurisdiction trial-consolidation
Key Terms:
Jurisdiction ClassAction JusticiabilityDoctri
Latest Conference: 2025-01-24
Question Presented (AI Summary)

Whether plaintiffs' intent matters in assessing if plaintiffs have 'proposed' a joint trial of the claims of 100 or more persons pursuant to 28 U.S.C. § 1332(d)(11)?

Question Presented (OCR Extract)

QUESTION PRESENTED The Class Action Fairness Act of 2005 (““CAFA”) vests federal courts with subject matter jurisdiction over mass actions “in which monetary relief claims of 100 or more persons are proposed to be tried jointly on the ground that the plaintiffs’ claims involve common questions of law or fact.” 28 U.S.C. § 1332(d)(11). After filing nine identical complaints—each consisting of just under 100 plaintiffs, but collectively more than 800 moved to consolidate the cases under a Connecticut state court rule that expressly and solely provides for consolidation “for trial.” Conn. Prac. Book § 9-5. Defendants thereafter removed the nine cases under CAFA. The Second Circuit nevertheless affirmed the District Court’s decision to remand the cases to state court on the basis that Plaintiffs did not “intend” to seek trial consolidation. The question presented is: Whether plaintiffs’ intent matters in assessing if plaintiffs have “proposed” a joint trial of the claims of 100 or more persons pursuant to 28 U.S.C. § 1332(d)(11)? (i)

Docket Entries

2025-01-27
Petition DENIED.
2025-01-08
DISTRIBUTED for Conference of 1/24/2025.
2025-01-06
Reply of Boehringer Ingelheim Pharmaceuticals, Inc., et al. submitted.
2025-01-06
Reply of petitioners Boehringer Ingelheim Pharmaceuticals, Inc., et al. filed. (Distributed)
2024-12-20
Brief of Beth Bacher, Representative for Paul Bacher (Deceased), et al. in opposition submitted.
2024-12-20
Brief of respondents Beth Bacher, Representative for Paul Bacher (Deceased), et al. in opposition filed.
2024-12-20
2024-10-30
Motion to extend the time to file a response is granted and the time is extended to and including December 23, 2024. See Rule 30.1.
2024-10-28
Motion to extend the time to file a response from November 22, 2024 to December 22, 2024, submitted to The Clerk.
2024-10-21
Petition for a writ of certiorari filed. (Response due November 22, 2024)

Attorneys

Beth Bacher, Representative for Paul Bacher (Deceased), et al.
John Anthony BrueggerParafinczuk Wolf, P.A., Respondent
John Anthony BrueggerParafinczuk Wolf, P.A., Respondent
Boehringer Ingelheim Pharmaceuticals, Inc., et al.
Daniel S. PariserArnold and Porter Kaye Scholer LLP, Petitioner
Daniel S. PariserArnold and Porter Kaye Scholer LLP, Petitioner